Medication Assisted Therapy

Most clinicians opt for Naltrexone as first line for alcohol use disorder (AUD) although Acamprosate may be slightly more effective at reducing urges. Naltrexone is a once daily medication, affordable, and has a relatively low side effect profile. Disulfram is typically considered as a last option given the significant adverse reaction if the patient uses with alcohol. In addition to these three options, topiramate and gabapentin seem to be an effective option for treating AUD, and are supported by evidence suggesting benefit; however, topiramate and gabapentin are not yet first line. Click on the title for a detailed, printable PDF.

fr.com-Acamprosate-MAT-drug.jpg

Acamprosate / “Campral”

Dose: 666 mg PO TID

Primary Indication

  • Start ASAP after withdrawal when abstinence achieved; continue treatment even if relapse.

  • Adverse Reactions RARE, but include: Severe- suicidality, depression; Common- diarrhea, insomnia, anxiety, depression, asthenia, xerostomia

  • Retail Cost (without insurance): ~$230 for 180 tablets, GoodRx: ~ $67.50 for 180 tablets

  • Dosing: CrCl 30-50: 333 mg TID; CrCl <30: contraindicated. Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined

Evidence for acamprosate

naltrexone.jpeg

Naltrexone / “Revia”

Dose: 50mg PO QD

Primary Indication

  • Must be opioid free for 7-10 days to consider this option. Cautions: depression, suicidal ideation.

  • Adverse Reactions RARE, but include: Severe- suicidality, depression, hepatotoxicity; common- insomnia, nausea, vomiting, anxiety, headache, constipation

  • Retail Cost (without insurance): ~$35 for 30 tablets, GoodRx: ~$21.65 for 30 tablets

  • Dosing: caution with renal and hepatic impairment

Evidence for naltrexone

 
fr.com-Disulfiram-MAT-drug.jpg

Disulfiram / “Antabuse”

Dose: 125-500 mg PO QAM

Secondary Indication, if resistant to other medications

  • Start 500 mg PO qAM for 1-2 weeks, Maintenance 250 mg PO qAM

  • Patient must be abstinent from alcohol for >12 hours

  • Adverse Reactions RARE, but include: Severe - disulfiram-alcohol reaction (severe), psychosis, hepatotoxicity, peripheral neuropathy, optic neuritis. Common- rash, drowsiness, impotence, headache, metallic taste

  • Retail Cost (without insurance)- $175 for 30 tablets, GoodRx: ~ 25.55 for 30 tablets

  • Dosing: caution with renal and hepatic impairment

Evidence for disulfram

Topamax.jpg

Topirimate/ “Topamax”

Dose 100-150 mg PO daily

Non FDA Approved, but new studies suggest efficacy

  • Start 25 mg PO in the morning and titrate weekly to effective dose, up to 75 mg daily.

  • Many study participants experience side effects, however, most are minor.

  • Adverse reactions include: Dizziness, somnolence, nervousness, numbness/paresthesia, psychomotor slowness, nausea.

  • Retail cost (without insurance) - $52 for 30 tablets, GoodRx ~$9.50 (lowest cost $3.00) for 30 tablets

  • Dosing: caution with hepatic impairment, but often, this will improve with cessation of alcohol.

    Evidence for topiramate

Gabapentin/ “Neuraptine”

Dose 900-1800 mg PO daily

Non FDA Approved, but many studies suggest efficacy

  • Titrate up, starting at 300 mg daily for 5 days minimum per dose.

  • Common side effects include dizziness, somnolence, ataxia, and fatigue.

  • Retail cost (without insurance) - $9-20 per month for 90 capsules of 300 mg.

  • Dosing: get a creatnine at baseline. Monitor for suicidality

What’s the deal with SSRI use and initiation of the above medications?

There have been several studies that address the use of selective serotonin reuptake inhibitors (SSRIs) and treatment of unhealthy alcohol use. While SSRIs may improve concomitant depression, there is no evidence from recent meta-analyses that SSRIs, including citalopram, reduce drinking volume or drinking days.

If your patient is already on an SSRI, it IS safe to start an additional medication for reducing risky alcohol use. A 2008 study demonstrated that patients on both an SSRI and naltrexone had greater reduction of alcohol use and drinking days as compared to SSRI alone.

 

FAQ

My patient has Hep C and some depression. Can I still use these medications?

 

In what scenario should I not be prescribing MAT and refer to a psychiatrist?

 

Yes, as long as there is no significant hepatic damage/elevated LFT’s, it is ok to start medications (naltrexone, acamprosate). Check LFTs Q 1-2 months.

If you’re concerned about multiple co-morbidities, or significant suicidality, the patient may benefit from seeing a psychiatrist. If your intuition says, “This might not be safe,” it’s reasonable to refer!


Need more medication help?

The National Institute for Alcohol Abuse and Alcoholism has excellent resources, including a treatment navigator.

Check out this link from the National Institute on Drug Abuse to get full prescribing guide by RAND or click the link below to send for a warm handoff.